Discussing DED treatment cost can help build trust and lead to more same-day procedures November 28, 2023 Cory Lappin, OD shares his strategies for getting comfortable with talking treatment costs
How a Boutique Dry Eye Clinic in an Unexpected Spot Drew $45,000 in the First 9 Months.
Press PublicationsDry Eye How a Boutique Dry Eye Clinic in an Unexpected Spot Drew $45,000 in the First 9 Months. March 13, 2024 Marinda Hofacre, OD Marinda Hofacre, OD, is
Teaching Peers About Dry Eye Disease Boosts Patients’ Access to Care
Press PublicationsDry Eye Teaching Peers About Dry Eye Disease Boosts Patients’ Access to Care May 7, 2024 Pamela E. Theriot, OD, FAAO Dry Eye Relief Center at Lusk Eye Specialists
Lumenis’s OptiPLUS Delivers Clinically Significant Results for DED
Ray Corbin-Simon, OD, shares how OptiLIGHT and OptiPLUS have elevated her eye care practice by addressing her patients’ various needs.
Revolutionizing Dry Eye Treatment
Dr. Celesta Ferreira shares how OptiLIGHT and OptiPLUS by Lumenis transformed her dry eye treatment approach, providing patients with lasting relief from meibomian gland dysfunction.
The 2024 IPL Report
Discover why OptiLIGHT stands out in the latest 2024 IPL Report! See how over 500 optometrists are using IPL to treat dry eye disease, improve patient outcomes, and overcome treatment challenges. Uncover the benefits, ROI, and why OptiLIGHT is a top choice for Dry Dye Disease management due to MGD!
Lumenis’ triLift™ Honored in Two Categories on the MedEsthetics 2025 Readers’ Choice Awards
triLift™ honored as the “Best Non-Invasive Facelifting Device” and the “Best Light & Energy-Based Device” categories for its breakthrough technology in facial muscle stimulation. Renowned awards program celebrates excellence in aesthetics as chosen by industry professionals and readers.
Yan et al. (2021): The Efficacy of Intense Pulsed Light Combined With Meibomian Gland Expression for the Treatment of Dry Eye Disease Due to Meibomian Gland Dysfunction: A Multicenter, Randomized Controlled Trial
In a prospective, multicenter, randomized control trial, Lumenis IPL with OPT™ combined with MGX significantly improved signs and symptoms of DED due to MGD.
Fishman et al (2020): Real-Time Video Microscopy of In Vitro Demodex Death by Intense Pulsed Light
An in-vitro study demonstrated that, with settings used for treatment of dry eye due to meibomian gland dysfunction (MGD), Lumenis IPL with OPTTM destroyed an isolated Demodex mite.
Choi et al (2019): Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines
In a prospective, single arm study, Lumenis IPL with OPT™ improved signs and symptoms of Dry Eye Disease due to MGD, and decreased tear levels of key inflammation markers. The decrease of two of these markers were correlated with improvement in meibum expressibility.